A critical role of hepatic GABA in the metabolic dysfunction and hyperphagia of obesity

Caroline E Geisler  
*University of Arizona*

Susma Ghimire  
*University of Arizona*

Stephanie M Bruggink  
*University of Arizona*

Kendra E Miller  
*University of Arizona*

Savanna N Weninger  
*University of Arizona*

See next page for additional authors

Follow this and additional works at: [https://digitalcommons.wustl.edu/open_access_pubs](https://digitalcommons.wustl.edu/open_access_pubs)

Please let us know how this document benefits you.

**Recommended Citation**

Geisler, Caroline E; Ghimire, Susma; Bruggink, Stephanie M; Miller, Kendra E; Weninger, Savanna N; Kronenfeld, Jason M; Yoshino, Jun; Klein, Samuel; Duca, Frank A; and Renquist, Benjamin J, "A critical role of hepatic GABA in the metabolic dysfunction and hyperphagia of obesity," *Cell Reports*. 35, 13. 109301 (2021).  
[https://digitalcommons.wustl.edu/open_access_pubs/10627](https://digitalcommons.wustl.edu/open_access_pubs/10627)

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact [vanam@wustl.edu](mailto:vanam@wustl.edu).
A critical role of hepatic GABA in the metabolic dysfunction and hyperphagia of obesity

Highlights

- Liver GABA-T knockdown or inhibition decreases serum insulin in DIO mice
- Liver GABA-T knockdown improves insulin sensitivity and muscle glucose uptake
- Liver GABA-T knockdown decreases food intake and body mass in DIO mice
- Liver GABA-T expression is positively correlated with insulin in people with obesity

In brief

Geisler et al. show that GABA-transaminase catalyzes GABA synthesis in the liver of obese mice, resulting in hyperinsulinemia, insulin resistance, and hyperphagia. In people with obesity, liver GABA-transaminase expression is positively associated with hyperinsulinemia. Thus, GABA-transaminase inhibitors may be effective at restoring glucose homeostasis in obese, hyperinsulinemic, insulin-resistant individuals.
A critical role of hepatic GABA in the metabolic dysfunction and hyperphagia of obesity

Caroline E. Geisler,1,2 Susma Ghimire,1 Stephanie M. Bruggink,1 Kendra E. Miller,1 Savanna N. Weninger,1 Jason M. Kronenfeld,1 Jun Yoshino,3 Samuel Klein,3 Frank A. Duca,1 and Benjamin J. Renquist1,4,*

1School of Animal and Comparative Biomedical Sciences, University of Arizona, Tucson, AZ 85721, USA
2Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
3Center for Human Nutrition, Washington University School of Medicine, St. Louis, MO, USA
4Lead contact
*Correspondence: bjrenquist@email.arizona.edu
https://doi.org/10.1016/j.celrep.2021.109301

SUMMARY

Hepatic lipid accumulation is a hallmark of type II diabetes (T2D) associated with hyperinsulinemia, insulin resistance, and hyperphagia. Hepatic synthesis of GABA, catalyzed by GABA-transaminase (GABA-T), is up-regulated in obese mice. To assess the role of hepatic GABA production in obesity-induced metabolic and energy dysregulation, we treated mice with two pharmacologic GABA-T inhibitors and knocked down hepatic GABA-T expression using an antisense oligonucleotide. Hepatic GABA-T inhibition and knockdown decreased basal hyperinsulinemia and hyperglycemia and improved glucose intolerance. GABA-T knockdown improved insulin sensitivity assessed by hyperinsulinemic-euglycemic clamps in obese mice. Hepatic GABA-T knockdown also decreased food intake and induced weight loss without altering energy expenditure in obese mice. Data from people with obesity support the notion that hepatic GABA production and transport are associated with serum insulin, homeostatic model assessment for insulin resistance (HOMA-IR), T2D, and BMI. These results support a key role for hepatocyte GABA production in the dysfunctional glucoregulation and feeding behavior associated with obesity.

INTRODUCTION

Type II diabetes (T2D) affects 30 million Americans, and an additional 81 million Americans have pre-diabetes (Centers for Disease Control and Prevention, 2017). Thus, 46% of the US adult population is affected by diabetes, the 7th leading cause of death in America, which consumes 1 in every 7 US health care dollars (American Diabetes Association, 2018). The high prevalence, mortality, and economic burden of T2D underscores a critical need for the development of additional therapeutics to treat diabetes.

Hepatic steatosis is a hallmark of T2D, as accumulation of hepatic lipids strongly correlates with the severity of peripheral insulin resistance and hyperinsulinemia (Chang et al., 2013; Chon et al., 2016; Kotronen et al., 2008). Furthermore, 87% of diabetics are overweight or obese (Centers for Disease Control and Prevention, 2017). Obesity and T2D are also characterized by dysregulated energy homeostasis, particularly diminished meal-induced satiety, which can result in excessive energy intake (Erdmann et al., 2005; Knudsen et al., 2014; Timper and Bruning, 2017). Interestingly, hepatic lipid accumulation is directly associated with increased energy intake. In individuals with non-alcoholic fatty liver disease (NAFLD), the percent hepatic steatosis positively correlates with total energy intake and carbohydrate intake (Gonzalez et al., 2013). These findings suggest the possibility that hepatic lipid accumulation may drive obesity-induced hyperinsulinemia, insulin resistance, and hyperphagia.

The liver produces and releases hepatokines into circulation in response to acute and chronic nutrient status (Meex and Watt, 2017). For example, FGF21 and ANGPTL4 are secreted from hepatocytes in response to liver nutrient flux and can act in an endocrine fashion to impact whole-body metabolism. In line with this, we have recently established that obesity-induced hepatic lipid accumulation increases hepatocyte production and release of the inhibitory neurotransmitter, GABA, in mice (Figure 4A in Geisler et al., 2021 [this issue of Cell Reports]) that we hypothesize acts in a paracrine fashion to decrease the firing activity of the hepatic vagal afferent nerve (HVAN) to regulate insulin secretion and sensitivity (Figure 5 in Geisler et al., 2021). These findings provide a mechanistic link explaining how hepatic lipid accumulation, though increasing extracellular hepatocyte-produced GABA to impair HVAN signaling, drives the development of metabolic diseases.

The GABA shunt classically refers to a tricarboxylic acid cycle detour that converts α-ketoglutarate to succinate and concomitantly breaks down a molecule of GABA via GABA-transaminase (GABA-T) (Hassel et al., 1998). However, in the liver, GABA-T mediates GABA synthesis (White, 1981). We have proposed that hepatic lipids activate reversed GABA shunt activity in hepatocytes and that hepatic GABA and glucose production are metabolically linked (Figure 5 in Geisler et al., 2021). It remains completely untested whether manipulating this GABA shunt can prevent hepatic-steatosis-derived metabolic disease.
Figure 1. GABA-transaminase inhibition improves glucose homeostasis in obesity

HFD-induced obese mice were treated with GABA-transaminase inhibitors ethanolamine-O-sulfate (EOS) or vigabatrin (8 mg/day) or phosphate-buffered saline (PBS) (control) for 5 days.

(A and B) Bars that do not share a common letter differ significantly within injection treatment (p < 0.05; number below bar denotes n per group).

(A) Body weight during treatment.

(B–D) Basal serum insulin (B), glucose (C), and glucose:insulin ratio (D) pre-treatment, on treatment day 4, and after a 2-week washout.

(E) Serum glucagon in response to EOS.

(F and G) Oral glucose tolerance (OGTT) (F) and OGTT area under the curve (AUC) (G) on treatment day 4.

(legend continued on next page)
Thus, GABA-T represents a promising target to decrease hyperinsulinemia and insulin resistance by limiting hepatic GABA production. Accordingly, in the current manuscript, we employed two models to limit hepatic GABA production: (1) pharmacologic inhibition of GABA-T activity and (2) antisense oligonucleotide (ASO)-mediated knockdown of hepatic-specific GABA-T expression. Using these models, we assessed systemic glucose homeostasis to examine the causative role between obesity-induced hepatic GABA production and obesity-induced hyperinsulinemia and insulin resistance. We also assessed food intake and energy expenditure to understand the role of hepatic GABA production in the dysregulation of energy homeostasis in obesity.

RESULTS

GABA-T inhibition improves glucose homeostasis in obesity

To directly assess the role of GABA-T in obesity-induced metabolic dysfunction, we treated high-fat-diet (HFD)-induced obese mice with one of two irreversible GABA-T inhibitors, ethanol-amino-O-sulfate (EOS) or vigabatrin (8 mg/day intraperitoneally [i.p.]) or phosphate-buffered saline vehicle. Both inhibitors reduce hepatic GABA-T activity by over 90% within 2 days (Qume and Fowler, 1996). Through 5 days of treatment, body weight remained similar among EOS-, vigabatrin-, and saline-injected mice (Figure 1A). 4 days of EOS or vigabatrin treatment decreased serum insulin and glucose concentrations and increased the glucose:insulin ratio relative to pre-treatment (Figures 1B–1D). 2-week washout from EOS or vigabatrin resulted in a return of serum insulin and the glucose:insulin ratio to pre-treatment levels (Figures 1B–1D). EOS treatment (5 days) decreased glucose secretion during an oral glucose tolerance test (OGTT) (raw area under the curve [AUC]), but not relative glucose clearance (delta AUC) was improved by 4 days of GABA-T inhibition (Figures 1F and 1G). Coincident with this improved clearance, glucose-stimulated serum insulin was decreased by vigabatrin and tended to be decreased by EOS relative to pre-treatment concentrations (Figure 1H). 2-week washout from EOS and vigabatrin markedly increased glucose-stimulated serum insulin (Figure 1H). Both GABA-T inhibitors improved insulin sensitivity assessed by insulin tolerance test (ITT) within 4 days of initiating treatment (Figures 1I and 1J). As oral drug delivery is preferred in clinic, we conducted another series of studies with EOS provided in the drinking water (3 g/L) for 4 days. EOS in the drinking water similarly improved glucose clearance, we subsequently measured cyclic guanosine monophosphate (cGMP), a key second messenger downstream of nitric oxide (NO) signaling that regulates blood flow (Archer et al., 1994). EOS increased cGMP in the soleus (59%) but had no effect in quad (Figure 1L).

In lean mice, which have low hepatic GABA production (Figures 4A and 4B in Geisler et al., 2021), there was no effect of EOS or vigabatrin (8 mg/day i.p.) on serum insulin concentrations or insulin sensitivity (Figures S1I, S1O, and S1P). In lean mice, GABA-T inhibition decreased glucose-stimulated serum insulin (Figure S1N).

Hepatic GABA-T knockdown improves obesity-induced metabolic dysfunction

To overcome the limitation of global pharmacologic inhibitors, we next used an ASO model to specifically knockdown hepatic GABA-T expression. Peripherally administered ASOs do not cross the blood brain barrier (Jaeger and Banks, 2005). Outside the central nervous system, the liver and pancreas express the most GABA-T (Uhlen et al., 2015). A GABA-T targeted ASO (12.5 mg/kg i.p. twice weekly) decreased hepatic GABA-T mRNA expression by >98% within 1 week. Importantly, this GABA-T-targeted ASO did not affect pancreatic or whole-brain GABA-T mRNA expression (Figure 2A). To establish the key role of GABA-T in liver slice GABA production, we measured ex vivo liver slice GABA release. GABA-T knockdown cut obesity-induced liver slice GABA release by 61% (Figure 2B). 1 week of GABA-T knockdown in obese mice did not affect body weight but decreased basal serum insulin and glucose concentrations and elevated the glucose:insulin ratio (Figures 2C–2F). GABA-T-targeted ASO injections also improved oral glucose clearance without affecting oral glucose stimulated serum insulin concentrations (Figures 2G–2I) and improved insulin sensitivity compared to scramble control ASO-injected mice (Figures 2J and 2K). These findings directly implicate hepatic GABA-T production in the development of obesity-induced hyperinsulinemia and insulin resistance.

Compared with control ASO, chronic (4-week) GABA-T ASO treatment decreased ex vivo liver slice GABA release and decreased body mass and serum insulin while increasing the glucose:insulin ratio (Figures S2A–S2C and S2E). Thus, the metabolic response to GABA-T knockdown persists. Admittedly, a decrease in body mass with chronic ASO treatment could contribute to the improvements in glucose homeostasis.

To assess the effect of GABA-T knockdown on insulin action before body mass is affected, we performed hyperinsulinemic-euglycemic clamp in diet-induced obese mice treated with scramble control or GABA-T-targeted ASOs for 1 week. Body weight on the day of clamp was not affected by treatment.
All time points are relative to the onset of insulin (4 mU/kg/min) and variable rate 3-[3H]-D-glucose in dextrose infusion at time 0, with the basal period referencing pre-0 measurements. Blood glucose concentrations were lower in GABA-T ASO-treated mice during the first 20 min of the clamp, but not different between ASO treatments from 30 to 120 min of the clamp, during which euglycemia was achieved in both groups (Figure 3B). To maintain the same level of euglycemia, GABA-T knockdown mice required a higher glucose infusion rate (GIR) (mg/kg/min), which was significant from 30 to 120 min of the clamp (Figure 3C). Plasma insulin concentrations did not differ by ASO treatment during either the basal period or during the clamp (Figure 3D). Importantly, insulin concentrations were elevated during the clamp (Figure 3D; p = 0.013). GABA-T
knockdown did not affect the rate of endogenous glucose appearance (Ra) during the basal or clamp periods (Figure 3E). The basal rate of glucose disappearance (Rd) did not differ between ASO treatments. However, hyperinsulinemia during the clamp nearly doubled Rd in GABA-T knockdown, but not control, mice (Figure 3F). After 120 min of the clamp, mice received a bolus of 14C-2-deoxyglucose and were sacrificed 30 min later to assess tissue-specific glucose uptake. GABA-T knockdown improved glucose uptake by the soleus, quadriceps, and gastrocnemius skeletal muscles (Figure 3G).

In chow-fed mice, hepatic GABA production is limited (Figures 4A and 4B in Geisler et al., 2021). In turn, we expected minimal responses to inhibition of the GABA shunt in lean mice. We tested two GABA-T-targeted ASOs that both decreased hepatic GABA-T mRNA expression by >80% within 1 week and >94% after 4 weeks of treatment. Neither altered pancreatic or whole-brain GABA-T mRNA expression (Figures S3A and S3B). Chronic (4-week) GABA-T knockdown did not affect body weight or glucose homeostasis measures in lean mice (Figures S3C–S3K). This agrees with our observations that acute GABA-T inhibition with EOS does not alter glucose homeostasis in lean mice (Figures S1I–S1P). Instead, beneficial effects of GABA-T inhibition are specific to obesity, due to an increase in the GABA shunt activity and subsequent hepatic GABA production.

The hepatic vagal nerve is essential to improvements in glucose homeostasis resulting from GABA-T inhibition or knockdown

Hepatic vagotomy prevents the liver from altering afferent signaling to the brain, without affecting normal vagal afferent input originating from cell bodies in the nodose ganglia (Peters et al., 2013). In turn, we expect that vagotomy prevents inhibition of the vagal afferent tone by GABA produced in the liver. We hypothesize that hepatic GABA mediates the effects that we have observed in the liver. 

Figure 3. 1 week of hepatic GABA-transaminase knockdown improves insulin sensitivity assessed by hyperinsulinemic euglycemic clamp

High-fat-diet-induced obese mice received 1 week of injections with a GABA-T targeted or scramble control ASO (12.5 mg/kg i.p. twice weekly) before hyperinsulinemic euglycemic clamps were performed.

(A) Body weight the day of clamp procedures.
(B and C) Blood glucose concentrations (B) and glucose infusion rate during the clamps (C).
(D) Serum insulin concentrations before insulin infusion (basal) and during the clamp.
(E and F) Endogenous glucose appearance (Ra) (E) and glucose disappearance (Rd) (F) before insulin infusion (basal) and during the clamp.
(G) Tissue specific 14C-2-deoxyglucose uptake (PR, perirenal adipose tissue; WAT, white adipose tissue).
Number below bar denotes n per group. All data are presented as mean ± SEM.
Figure 4. Obesity-induced hepatic GABA production increases phagic drive
Cumulative food intake and body mass during the first 2 weeks of GABA-T targeted or scramble control ASO injections (12.5 mg/kg i.p. twice weekly) in lean (A and B) and diet-induced obese (C–G) mice. Cumulative light cycle, dark cycle, and daily food intake (A) and cumulative body mass change (B) in lean mice are shown. Cumulative light cycle, dark cycle, and daily food intake (C) and cumulative body mass change (D) in obese mice are shown. Weekly cumulative food intake (E), cumulative body weight change (F), and body mass (G) during ASO treatment are shown. Body mass during chronic EOS treatment is shown (3 g/L in drinking water). All data are presented as mean ± SEM.
reported by acting on the HVAN to induce hyperinsulinemia and insulin resistance. Accordingly, we assessed the effect of EOS treatment in HFD-induced obese hepatic vagotomized and sham-operated mice. Although body weight did not differ between surgical groups during EOS treatment (Figure S4A), the response to EOS was dependent on an intact hepatic vagal nerve. In sham-operated mice, EOS decreased serum insulin and glucose, elevated the glucose:insulin ratio, improved oral glucose tolerance, diminished glucose-stimulated serum insulin concentrations, and tended to improve insulin sensitivity as measured by an ITT (Figures S4B and S4K). Washout restored all parameters to pre-treatment measures. Vagotomy eliminated most of the responses to EOS (Figures S4B–S4L). Because we propose that hepatic GABA production supports gluconeogenic flux (Figure 5 in Geisler et al., 2021), we expected GABA-T inhibition to decrease gluconeogenesis through direct actions at the liver. In turn, diminished hepatic glucose output explains the vagal nerve independent decrease in serum glucose during EOS treatment in hepatic vagotomized mice (Figure S4C).

We next assessed the effect of 4 weeks of GABA-T knockdown (12.5 mg/kg GABA-T-targeted ASO i.p. twice weekly) in diet-induced, obese, sham-operated and hepatic vagotomized mice. Consistent with previous observations (Figure 1B in Geisler et al., 2021), pre-treatment body weight was lower in obese, vagotomized mice compared to sham-operated control mice (Figure S2G). GABA-T knockdown decreased basal serum insulin in sham, but not in vagotomized, mice (Figure S6B). As shown with pharmacological GABA-T inhibition (EOS), GABA-T knockdown decreased basal serum glucose concentrations independent of the hepatic vagal nerve (Figure S2I), again likely due to reduced hepatic glucose output. After 4 weeks of GABA-T ASO injections, serum glucagon oral glucose tolerance, glucose-stimulated serum insulin, and insulin sensitivity were not different between surgical treatments (Figures S2K–S2P). Hepatic vagotomy protects against obesity-induced glucose intolerance and insulin resistance (Figure 1 in Geisler et al., 2021). Here, we show that GABA-T knockdown allowed sham-operated animals to achieve similar glucose tolerance, glucose-stimulated serum insulin, and insulin sensitivity to that measured in hepatic vagotomized mice. Hepatic vagotomy lowers serum insulin, improves glucose tolerance, and improves insulin sensitivity, recapitulating the response to GABA-T ASO-mediated knockdown or GABA-T pharmacological inhibition. This further supports our hypothesis that an obesity-induced increase in hepatic GABA production relies upon the HVAN to induce hyperinsulinemia and insulin resistance.

GABA-T knockdown decreases fat mass by decreasing food intake without affecting energy expenditure in obesity

Given that hepatic GABA-T knockdown for 4 weeks decreased body weight in obese mice (Figure S2B), we hypothesized that GABA-T knockdown may decrease food intake or increase energy expenditure. Accordingly, we assessed daily food intake and body mass during the light and dark cycle for the first 2 weeks of ASO treatment in lean and obese mice. In lean mice, GABA-T knockdown did not affect cumulative light cycle, dark cycle, or daily food intake or daily body mass change (Figures 4A and 4B). In obese mice, GABA-T knockdown decreased cumulative light cycle, dark cycle, and daily food intake (Figure 4C). To ensure that the metabolic changes were not merely
a result of this decrease in food intake, we pair-fed mice to match the decrease in food consumption associated with GABA-T knockdown (Figure S5B). This 6.57% ± 0.34% dietary restriction did not affect the change in glucose during an OGTT or insulin sensitivity (Figures S5C–S5F). Cumulative weekly food intake remained lower through 4 weeks of GABA-T knockdown (Figure 4E). This suppression of food intake was accompanied by a decrease in body mass in GABA-T ASO-treated mice (Figures 4D and 4F). In fact, GABA-T knockdown continued to decrease body weight during 7 weeks of treatment (Figure 4G). Similarly, 7 weeks of continuous exposure to EOS in the drinking water (3 g/L) dramatically decreased body mass in diet-induced obese mice (Figure 4H). These data suggest that sensitivity to the weight loss effect of limiting hepatocyte GABA production is maintained throughout treatment but is less significant as body mass returns to normal.

Interestingly, GABA-T knockdown did not alter food intake in response to a 16-h fast in either chow-fed lean or HFD-induced obese mice (Figures S6A and S6B). This proposes that hepatic GABA signals to regulate ad libitum light and dark cycle food intake without affecting the fasting-induced drive for refeeding. Accordingly, GABA-T knockdown did not affect fasting mRNA expression of the canonical hypothalamic neuropeptides regulating food intake (neuropeptide Y [NPY], agouti-related peptide [AgRP], and pro-opiomelanocortin [POMC]; Figure S6C). Admittedly, we cannot rule out an effect of central GABA-T knockdown, as we did observe a 14% reduction in hypothalamic GABA-T expression at 7 weeks of GABA-T ASO injections (Figure S6D). 4 weeks of GABA-T ASO treatment did not affect either hypothalamic or whole-brain GABA-T mRNA expression (Figure S6D). Although ASOs do not cross the blood brain, it is possible that the ASO altered food intake or metabolic function by acting on circumventricular areas in the brain. Although we have not investigated the possible involvement of circumventricular GABA-T knockdown, data from the hepatic vagotomy model would suggest that the hepatic vagal nerve is involved (Figure S8B).

The anorexigenic hormone leptin induces satiety and weight loss, whereas leptin resistance in obesity contributes to hyperphagia and weight gain (Frederich et al., 1995; Halaas et al., 1995). We tested whether GABA-T knockdown in obesity may have improved leptin sensitivity as a potential mechanism to decrease appetite and cause weight loss. A single 6AM injection of leptin (2 mg/kg) did not affect food intake in either obese GABA-T or control ASO-treated mice at any time point, suggesting that all mice were leptin resistant (Figure S6E). Consistent with the decreased food intake previously observed in response to GABA-T knockdown, we again saw that GABA-T knockdown decreased light cycle, dark cycle, and 24-h food intake independent of injection (Figure S6E). Relative weight change was also not affected by leptin in control or GABA-T ASO obese mice (Figure S6F). Thus, enhanced leptin sensitivity is not mediating the diminished phagic drive in response to GABA-T knockdown in obesity. A single 6AM leptin injection decreased light cycle and 24-h food intake in chow-fed mice without affecting body weight (Figures S6G and S6H).

We next investigated whether altered energy expenditure contributed to the body mass loss with GABA-T knockdown in obesity. Energy expenditure (kcal/h), assessed by respiration calorimetry and corrected using the covariate of lean body mass, was not altered by 1 or 4 weeks of GABA-T knockdown (Figures S7A–S7C). In addition, there was no effect of GABA-T knockdown on the composition of oxidized macronutrients (respiratory exchange ratio [RER]), daily water intake, or daily activity (Figures S7D–S7I). Thus, the effects of GABA-T knockdown on body mass appear independent of energy expenditure or nutrient oxidation.

Body composition, assessed by dual-energy X-ray absorptiometry (DEXA), revealed that 4 weeks of GABA-T knockdown decreased total body mass and fat mass without affecting lean mass relative to control mice (Figures 5A–5C). The decreased fat mass with GABA-T knockdown suggests that weight loss induced by limiting hepatocyte GABA production reflects a loss of adiposity. We additionally assessed body composition on day 0 and 7 of providing obese mice with EOS in their drinking water (3 g/L). We found that EOS treatment decreased total body mass (10%), fat mass (16.27%), and lean mass (6.15%). Although there was a small loss of lean mass, diminished fat mass constitutes most of the lost body mass with EOS treatment.

**Hepatic vagotomy decreases light cycle food intake on HFD. GABA-T knockdown normalizes food intake in sham mice to that observed in vagotomized mice.**

We had previously reported that hepatic vagotomy decreased weight gain on a HFD (Figure 1B in Geisler et al., 2021). Here, we show that hepatic vagotomy decreases 1-week cumulative light cycle food intake by 22% in diet-induced obese mice, resulting in a 5.3% decrease in cumulative 24-h food intake (Figure S8A). We continued daily food intake measurements for the next 2 weeks as all mice were treated with the GABA-T-targeted ASO. In response to GABA-T knockdown, the previously observed difference in food intake in sham-operated and vagotomized mice was eliminated (Figures S8B and S8C). The GABA-T ASO resulted in a greater cumulative week 4 body mass loss in sham-operated than in vagotomized mice, which experienced no net change in body mass (Figure S8D). Thus, the glucoregulatory, phagic, and body mass changes in response to GABA-T knockdown all appear to be dependent on the HVAN. These data support that hepatic vagotomy eliminates the GABA-induced decrease in HVAN activity from being communicated to the brain and accordingly protects against obesity-induced perturbations of glucose and energy homeostasis.

**Associations between hepatic GABA system and glucoregulatory markers in humans with obesity.** To understand the potential clinical relevance of these findings, we assessed the hepatic mRNA expression of ABAT (encodes for GABA-T) and the 4 GABA transporters (SLC6A6, encodes for taurine transporter [Taut]; SLC6A8, encodes for GABA trans- porter 1 [GAT1]; and SLC6A12, encodes for the betaine-GABA transporter 1 [BGT1]; and SLC6A13, encodes for GABA transport- er 2 [GAT2]) in 19 people with obesity (age 45 ± 3 years old; 2 men and 17 women), who were carefully characterized by measuring intrahepatic triglyceride (IHTG) content using magnetic resonance imaging (MRI) and insulin sensitivity using the hyperinsulinemic-euglycemic clamp procedure (HECP) in conjunction with stable isotopically labeled glucose tracer.
Multivariate regressions, including intrahepatic triglyceride % (IHTG%), hepatic ABAT (GABA-T) mRNA, and the hepatic GABA transporter (SLC6A12) mRNA as explanatory variables for variations in serum insulin (A) or hepatic insulin sensitivity index (HISI) (B), ABAT and SLC6A12 mRNA (FPKM UQ; fragments per kilobase million reads upper quartile) were quantified by RNA sequencing (RNA-seq) from liver tissue. Single-nucleotide polymorphisms (SNPs) in the ABAT promoter are associated with a decreased risk of type 2 diabetes (T2D) (C). All data are presented as mean ± SEM.

**DISCUSSION**

The liver signals in an endocrine fashion through a myriad of hepatokines and metabolites that change with the degree of hepatic steatosis to reflect altered metabolic homeostasis (Holland et al., 2017; Meex and Watt, 2017; Petersen et al., 2016). We report liver-produced GABA is a steatosis-affected hepatokine that alters glucose homeostasis. Unlike other hepatokines, which act in an endocrine fashion, our findings suggest GABA is acting locally in a paracrine fashion on the parasympathetic nervous system to mediate its downstream metabolic effects. Muting hepatic GABA production by pharmacologic inhibition or ASO-mediated knockdown of GABA-T attenuates obesity-induced hyperinsulinemia and insulin resistance. Beyond the improvements in glucose homeostasis, hepatic GABA-T knockdown decreases food intake, causing a decrease in adiposity and weight loss.

**Glucose homeostasis**

Preventing hepatic GABA production improves insulin sensitivity primarily by increasing skeletal muscle glucose clearance (Figures 1K and 3G). Our results propose that some of the improvements in glucose clearance may be mediated by increased blood flow. Vasodilation of the microvasculature accounts for 40% of insulin-stimulated muscle glucose uptake (Vincent et al., 2003). Insulin and acetylcholine signaling at endothelial cells stimulates NO production, which signals to smooth muscle cells inducing cGMP production and vasodilation (Archer et al., 1994; Gericke et al., 2011). The microvascular vasodilatory response is reduced in obesity, directly contributing to systemic insulin resistance (Cleland et al., 1999; Indumathy et al., 2015; Van Guilder et al., 2006). We showed that EOS treatment increased soleus muscle cGMP concentrations (Figure 1L). Future work will focus on understanding how hepatic GABA signaling at the HVAN regulates endothelial NO production and muscle perfusion.

**Food intake regulation**

Although weight loss itself improves insulin sensitivity and metabolic health (Schenk et al., 2009), GABA-T knockdown improves glucose homeostasis independent of the decrease in food intake and body weight. 1 week of GABA-T ASO treatment does not
increase glucose clearance or insulin sensitivity (Figures S5C–S5F). Moreover, pair feeding to match the hypophagia caused by the GABA-T ASO did not improve glucose clearance or insulin sensitivity (Figures S5C–S5F).

The HVAN has long been implicated in transmitting liver-derived signals to the hindbrain to regulate feeding behavior (Langhans et al., 1985; Russek, 1963). Early work established that hepatic portal infusion of glucose, amino acids, and lipids suppresses food intake (Niijima and Meguid, 1995; Randich et al., 2001; Shurlock and Forbes, 1984; Tordoff and Friedman, 1986), although more recent studies support that carbohydrate signals originating from the liver regulate feeding behavior through HVAN-dependent mechanisms (López-Soldado et al., 2017; Visinoni et al., 2012). Peripheral satiation factors, including glucagon-like peptide-1 (GLP-1), cholecystokinin (CCK), lipids, and leptin, reduce food intake-dependent upon increasing gastric and hepatic vagal branch afferent firing, although the orexigenic hormone ghrelin suppresses vagal afferent tone (Cox and Randich, 1997; Date et al., 2002; Krieger et al., 2016; Niijima, 2011; Peters et al., 2006; Randich et al., 2001). We propose an addition to this regulation of vagal nerve activity by metabolites and gut hormones, suggesting that hepatic lipid accumulation stimulates hepatic GABA release to depress HVAN activity. Consistent with the effects of other appetite regulators, GABA-mediated suppression of HVAN activity would be expected to increase phagic drive; removal of this inhibitory signal would be expected to increase HVAN firing and reduce food intake. In lean mice, which have low levels of hepatic GABA release, GABA-T knockdown did not alter food intake. Thus, hepatocyte-released GABA represents an orexigenic signal enhanced by obesity.

Diet-induced obesity dysregulates the diurnal pattern of food intake. Mice on a Chow diet eat ~20% of their daily food intake during the light cycle; this increases to ~30% with HFD feeding (Kohsaka et al., 2007). In healthy mice, vagal afferent receptor populations are regulated by nutritional state, expressing an orexigenic profile during fasting and an anorexigenic profile upon refeeding (Dockray, 2014). In turn, in Chow-fed mice, anorexigenic mecha-stimuli more effectively stimulate gastric vagal afferent nerve activity during the light cycle (Kentish et al., 2013). These circadian patterns are lost with diet-induced obesity (Dockray, 2014; Kentish et al., 2016). Together, these changes promote increased food intake during the light cycle and support the hypothesis that the dysregulation of feeding behavior in obesity is partially mediated by aberrant vagal signaling.

In lean mice, hepatic vagotomy shifts the diurnal feeding pattern to increase light cycle food intake (Hepler et al., 2016; Louis-Sylvestre, 1978), potentially mediated by the loss of peripheral light cycle anorexigenic stimuli. We report that diet-induced obese, hepatic vagotomized mice eat less during the light cycle than sham-operated controls, suggesting that hepatic vagotomy protects against the obesity-induced increase in daytime feeding. We hypothesize that preventing the GABA-mediated depression of HVAN activity from reaching the hindbrain not only improves glycemic control (Figure 1 in Geisler et al., 2021) but decreases light cycle food intake, possibly explaining the decreased weight gain with HFD feeding in hepatic vagotomized mice (Figure 1B in Geisler et al., 2021). Further supporting a role of hepatic GABA in HFD-induced weight gain, we previously observed that inducing hepatic Kir2.1 expression limited hepatic GABA release and HFD-induced weight gain (Figure 3C in Geisler et al., 2021).

Conclusions

Weight loss by people with obesity is often difficult to achieve and maintain. It is likely that dysregulated satiety signaling impairs the effectiveness of weight loss strategies. This work identifies hepatic GABA production as a potential therapeutic target that independently improves systemic glucose homeostasis and decreases food intake in obesity. In people with obesity, hepatic GABA production and transport are associated with glucoregulatory markers, T2D, and BMI, supporting the potential translation of this work to improve metabolic health in people.

STAR METHODS

Detailed methods are provided in the online version of this paper and include the following:

- KEY RESOURCES TABLE
- RESOURCE AVAILABILITY
  - Lead contact
  - Materials availability
  - Data and code availability
- EXPERIMENTAL MODEL AND SUBJECT DETAILS
  - Animals
  - Hepatic Vagotomy Surgeries
  - Human Subjects
- METHOD DETAILS
  - Antisense Oligonucleotide Studies
  - GABA Transaminase Inhibitor Studies
  - Food Intake Studies
  - Fast-Induced Refeeding
  - Leptin Food Intake Study
  - ASO Energy Expenditure and Body Composition
  - EOS Body Composition
  - Hyperinsulinemic Euglycemic Clamps
  - Oral Glucose Tolerance Test
  - Insulin Tolerance Test
  - Liver Slice Explant Studies
  - GABA Analysis
  - 3H-2-deoxy-D-glucose Uptake Studies
  - cGMP Analysis
  - Liver Analysis
  - Serum Assays
  - Studies Conducted in Human Subjects
- QUANTIFICATION AND STATISTICAL ANALYSIS
  - Statistics

SUPPLEMENTAL INFORMATION

Supplemental information can be found online at https://doi.org/10.1016/j.celrep.2021.109301.
ACKNOWLEDGMENTS

The authors wish to thank Drs. Richard Lee and Mark Graham of Ionis Pharmaceuticals, Carlsbad, CA for providing both the GABA-T and control antisense oligonucleotides and the UC Davis MMPC Energy Balance, Exercise, & Behavior Core (NIH grant U24-DK092993) for performing energy expenditure and physical activity measurements by indirect respiratory calorimetry using CLAMS and assessing body composition by DEXA. This research was funded by the Arizona Biomedical Research Commission Early Stage Investigator Award (award no. ADHS14-082986; B.J.R.), American Heart Association Beginning Grant In Aid (award no. 15BGIA2509300; B.J.R.), Arizona Biomedical Research Commission Investigator Grant (award no. ADHS18-201472; B.J.R.), and the Cardiovascular Research (HLB) NIH T32 Training Grant (award no. T32HL007249; C.E.G.).

AUTHOR CONTRIBUTIONS

Experimental design and project conceptualization, C.E.G. and B.J.R.; performed experiments and wet lab analyses, C.E.G., S.G., S.M.B., and J.M.K.; wrote initial draft of manuscript, C.E.G.; generated figures, C.E.G.; reviewed and edited manuscript, C.E.G., S.G., S.M.B., K.E.M., J.M.K., S.N.W., F.A.D., J.Y., S.K., and B.J.R.; performed SNP analysis, K.E.M.; performed clamp surgeries and experiments, S.N.W. and F.A.D.; conducted human clinical trial, J.Y. and S.K.; performed surgeries, B.J.R.; analyzed statistics, B.J.R.

DECLARATION OF INTERESTS

The results presented in this paper have resulted in patent cooperation treaty application no. 62/511,753 and 62/647,468: METHODS AND COMPOSITIONS FOR REGULATING GLUCOSE HOMEOSTASIS, which has been licensed by Livendocrine, LLC, founded by B.J.R.

REFERENCES

American Diabetes Association (2018). Economic costs of diabetes in the U.S. in 2017. Diabetes Care 41, 917–928.

Archer, S.L., Huang, J.M., Hamp, V., Nelson, D.P., Shultz, P.J., and Weir, E.K. (1994). Nitric oxide and cGMP cause vasorelaxation by activation of a charybどtoxin-sensitive K channel by cGMP-dependent protein kinase. Proc. Natl. Acad. Sci. USA 91, 7583–7587.

Ayala, J.E., Bracy, D.P., Malabanan, C., James, F.D., Ansari, T., Fueger, P.T., McGinness, O.P., and Wasserman, D.H. (2011). Hyperinsulinemic-euglycemic clamps in conscious, unrestrained mice. J. Vis. Exp. (57), 3188.

Centers for Disease Control and Prevention (2017). National Diabetes Statistics Report, 2017 (Centers for Disease Control and Prevention).

Chang, Y., Jung, H.S., Yun, K.E., Cho, J., Cho, Y.K., and Ryu, S. (2013). Cohort study of non-alcoholic fatty liver disease, NAFLD fibrosis score, and the risk of incident diabetes in a Korean population. Am. J. Gastroenterol. 108, 1861–1868.

Chon, Y.E., Kim, K.J., Jung, K.S., Kim, S.U., Park, J.Y., Kim, D.Y., Ahn, S.H., Chon, C.Y., Chung, J.B., Park, K.H., et al. (2016). The relationship between type 2 diabetes mellitus and non-alcoholic fatty liver disease measured by controlled attenuation parameter. Yonsei Med. J. 57, 885–892.

Clendan, S.J., Petrie, J.R., Ueda, S., Elliott, H.L., and Connell, J.M. (1999). Insulin-mediated vasodilation and glucose uptake are functionally linked in humans. Hypertension 33, 554–558.

Cox, J.E., and Randich, A. (1997). CCK-8 activates hepatic vagal C-fiber afferents. Brain Res. 776, 189–194.

Date, Y., Murakami, N., Toshinai, K., Matsukura, S., Nilijima, A., Matsuo, H., Kangawa, K., and Nakazato, M. (2002). The role of the gastric afferent vagal nerve in ghrelin-induced feeding and growth hormone secretion in rats. Gastroenterology 123, 1120–1128.

Dockray, G.J. (2014). Gastrointestinal hormones and the dialogue between gut and brain. J. Physiol. 592, 2927–2941.

Erdmann, J., Lipp, F., Wagenpfel, S., and Schusdziarra, V. (2005). Differential association of basal and postprandial plasma ghrelin with leptin, insulin, and type 2 diabetes. Diabetes 54, 1371–1378.

Frederich, R.C., Hamann, A., Anderson, S., Lølønn, B., Lowell, B.B., and Flier, J.S. (1995). Leptin levels reflect body lipid content in mice: evidence for diet-induced resistance to leptin action. Nat. Med. 1, 1311–1314.

Geiser, C.E., Ghimire, S., Hepler, C., Miller, K.E., Bruggink, S.M., Kentch, K.P., Higgins, M.R., Banet, C.T., Yoshino, J., Klein, S., et al. (2021). Hepatocyte membrane potential regulates serum insulin and insulin sensitivity by altering hepatic GABA release. Cell Rep. 35, this issue, 109298–1–109298–13.

Gericke, A., Sniatecki, J.J., Mayer, V.G., Goloborodko, E., Patzak, A., Hess, J., and Pfeffer, N. (2011). Role of M1, M3, and M5 muscarinic acetylcholine receptors in cholinergic dilation of small arteries studied with gene-targeted mice. Am. J. Physiol. Heart Circ. Physiol. 300, H1602–H1608.

Gonzalez, C., de Ledinghen, V., Vergnol, J., Foucher, J., Le Bail, B., Carlier, S., Maury, E., Gin, H., and Rigalleau, V. (2013). Hepatic steatosis, carbohydrate intake, and food quotient in patients with NAFLD. Int. J. Endocrinol. 2013, 428542.

Halla, G.J.L., Gajiwala, K.S., Maffei, M., Cohen, S.L., Chait, B.T., Rabinowitz, D., Lallone, R.L., Burley, S.K., and Friedman, J.M. (1995). Weight-reducing effects of the plasma protein encoded by the obese gene. Science 269, 543–546.

Hassel, B., Johannessen, C.U., Sonnewald, U., and Fonnum, F. (1998). Quantification of the GABA shunt and the importance of the GABA shunt versus the 2-oxoglutarate dehydrogenase pathway in GABAergic neurons. J. Neurochem. 71, 1511–1518.

Hepler, C., Foy, C.E., Higgins, M.R., and Renquist, B.J. (2016). The hypophagic response to heat stress is not mediated by GPR109A or peripheral i-β3 butyrate. Am. J. Physiol. Regul. Integr. Comp. Physiol. 310, R992–R998.

Holland, W.L., Xia, J.Y., Johnson, J.A., Sun, K., Pearson, M.J., Sharma, A.X., Quitnner-Strom, E., Tippets, T.S., Gordillo, R., and Scherer, P.E. (2017). Inducible overexpression of adiponectin receptors highlight the roles of adiponectin-induced ceramidase signaling in lipid and glucose homeostasis. Mol. Metab. 6, 267–275.

Indumathy, J., Pal, G.K., Pal, P., Ananthanarayanan, P.H., Parija, S.C., Balachander, J., and Dutta, T.K. (2015). Association of sympathovagal imbalance with obesity indices, and abnormal metabolic biomarkers and cardiovascular parameters. Obes. Res. Clin. Pract. 5, 55–66.

Jaeger, L.B., and Banks, W.A. (2005). Transport of antiseNSE across the blood-brain barrier. Methods Mol. Med. 106, 237–251.

Kentish, S.J., Frisby, C.L., Kennaway, D.J., Wittert, G.A., and Page, A.J. (2013). Circadian variation in gastric vagal afferent mechanosensitivity. J. Neurosci. 33, 19238–19242.

Kentish, S.J., Vincent, A.D., Kennaway, D.J., Wittert, G.A., and Page, A.J. (2016). High-fat diet-induced obesity ablates gastric vagal afferent circadian rhythms. J. Neurosci. 36, 3199–3207.

Knudsen, S.H., Karstoft, K., and Solomon, T.P. (2014). Hyperglycemia abolishes meal-induced satiety by a dysregulation of ghrelin and peptide YY3-36 in healthy overweight/obese humans. Am. J. Physiol. Endocrinol. Metab. 306, E225–E231.

Kohsaka, A., Laposky, A.D., Ramsey, K.M., Estrada, C., Joshu, C., Kobayashi, Y., Turek, F.W., and Bass, J. (2007). High-fat diet disrupts behavioral and metabolic circadian rhythms. J. Neurosci. 33, E225–E231.

Korenblat, K.M., Fabbri, E., Mohammed, B.S., and Klein, S. (2008). Liver, muscle, and adipose tissue insulin action is directly related to intraplethoric triglyceride content in obese subjects. Gastroenterology 134, 1369–1375.

Kotronen, A., Juurinen, L., Liikikainen, M., Vehkavaara, S., and Yki-Jarvinen, H. (2006). Increased liver fat, impaired insulin clearance, and hepatic and adipose tissue insulin resistance in type 2 diabetes. Gastroenterology 135, 122–130.
Krebs, S., Fischaleck, M., and Blum, H. (2009). A simple and loss-free method to remove TRIzol contaminations from minute RNA samples. Anal. Biochem. 387, 136–138.

Krieger, J.P., Arnold, M., Pettersen, K.G., Lossel, P., Langhans, W., and Lee, S.J. (2016). Knockdown of GLP-1 receptors in vagal afferents affects normal food intake and glycemia. Diabetes 65, 34–43.

Langhans, W., Egli, G., and Scharrer, E. (1985). Selective hepatic vagotomy eliminates the hypophagic effect of different metabolites. J. Auton. Nerv. Syst. 13, 255–262.

Livak, K.J., and Schmittgen, T.D. (2001). Analysis of relative gene expression using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25, 402–408.

López-Soldado, I., Fuentes-Romero, R., Duran, J., and Guinovart, J.J. (2017). Effects of hepatic glycogen on food intake and glucose homeostasis are mediated by the vagus nerve in mice. Diabetologia 60, 1076–1083.

Louis-Sylvestre, J. (1978). Feeding and metabolic patterns in rats with truncal vagotomy or with transplanted beta-cells. Am. J. Physiol. 235, E119–E125.

Meex, R.C.R., and Watt, M.J. (2017). Hepatokines: linking nonalcoholic fatty liver disease and insulin resistance. Nat. Rev. Endocrinol. 13, 509–520.

Niijima, A. (2011). Hepatportal leptin sensors and their reflex effects on autonomic outflow in the rat. J. Obes. 2011, 518842.

Niijima, A., and Meguid, M.M. (1995). An electrophysiological study on amino acid sensors in the hepato-portal system in the rat. Obes. Res. 3 (Suppl 5), 741S–745S.

Peters, J.H., Simasko, S.M., and Ritter, R.C. (2006). Modulation of vagal afferent excitation and reduction of food intake by leptin and cholecystokinin. Physiol. Behav. 89, 477–485.

Peters, J.H., Gallaher, Z.R., Ryu, V., and Czaja, K. (2013). Withdrawal and restoration of central vagal afferents within the dorsal vagal complex following subdiaphragmatic vagotomy. J. Comp. Neurol. 521, 3584–3599.

Petersen, M.C., Madiraju, A.K., Gassaway, B.M., Marcel, M., Nasiri, A.R., Butrico, G., Marucci, M.J., Zhang, D., Abulizi, A., Zhang, X.-M., et al. (2016). Insulin receptor Thr1160 phosphorylation mediates lipid-induced hepatic insulin resistance. J. Clin. Invest. 126, 4361–4371.

Qume, M., and Fowler, L.J. (1996). Effects of chronic oral treatment with GABA-transaminase inhibitors on the GABA system in brain, liver, kidney, and plasma of the rat. Biochem. Pharmacol. 52, 1355–1363.

Ramakers, C., Ruijter, J.M., Deprez, R.H., and Moorman, A.F. (2003). Assumption-free analysis of quantitative real-time polymerase chain reaction (PCR) data. Neurosci. Lett. 339, 62–66.

Randich, A., Spraggs, D.S., Cox, J.E., Meier, S.T., and Kelm, G.R. (2001). Jejunum or portal vein infusions of lipids increase hepatic vagal afferent activity. Neuroreport 12, 3101–3105.

Russek, M. (1963). Participation of hepatic glucoreceptors in the control of intake of food. Nature 197, 79–80.

Schenk, S., Harber, M.P., Shrivastava, C.R., Burtan, C.F., and Horowitz, J.F. (2009). Improved insulin sensitivity after weight loss and exercise training is mediated by a reduction in plasma fatty acid mobilization, not enhanced oxidative capacity. J. Physiol. 587, 4949–4961.

Seth, P.P., Vasquez, G., Allerson, C.A., Berdeja, A., Gaus, H., Kinberger, G.A., Prakash, T.P., Migawa, M.T., Bhat, B., and Swayze, E.E. (2010). Synthesis and biophysical evaluation of 2′,4′-constrained 2′O-methoxysterethyl and 2′,4′-constrained 2′O-ethyl nucleic acid analogues. J. Org. Chem. 75, 1569–1581.

Shurlock, T.G., and Forbes, J.M. (1984). Effects on voluntary food intake of infusions of glucose and amino acids into the hepatic portal vein of chickens. Br. Poult. Sci. 25, 303–308.

Timper, K., and Bruning, J.C. (2017). Hypothalamic circuits regulating appetite and energy homeostasis: pathways to obesity. Dis. Model. Mech. 10, 679–689.

Tordoff, M.G., and Friedman, M.J. (1986). Hepatic portal glucose infusions decrease food intake and increase food preference. Am. J. Physiol. 251, R192–R196.

Uhlén, M., Fagerberg, L., Hallström, B.M., Lindskog, C., Oksvold, P., Marding, A., Sivertsson, Å., Kampf, C., Sjöstedt, E., Asplund, A., et al. (2015). Proteomics. Tissue-based map of the human proteome. Science 347, 1260419.

Van Gulder, G.P., Hoetzer, G.L., Dengel, D.R., Stauffer, B.L., and DeSouza, C.A. (2006). Impaired endothelium-dependent vasodilation in normotensive and normoglycemic obese adult humans. J. Cardiovasc. Pharmacol. 47, 310–313.

Vincent, M.A., Barrett, E.J., Lindner, J.R., Clark, M.G., and Rattigan, S. (2003). Inhibiting NOS blocks microvascular recruitment and blunts muscle glucose uptake in response to insulin. Am. J. Physiol. Endocrinol. Metab. 285, E123–E129.

Visinoni, S., Khalid, N.F., Joannides, C.N., Shulkes, A., Yim, M., Whitehead, J., Tiganis, T., Lamont, B.J., Favaloro, J.M., Proietto, J., et al. (2012). The role of liver fructose-1,6-bisphosphatase in regulating appetite and adiposity. Diabetes 61, 1122–1132.

White, H.L. (1981). Glutamate as a precursor of GABA in rat brain and peripheral tissues. Mol. Cell. Biochem. 39, 253–259.
# STAR METHODS

## KEY RESOURCES TABLE

| REAGENT or RESOURCE                     | SOURCE                          | IDENTIFIER       |
|-----------------------------------------|---------------------------------|------------------|
| **Chemicals, peptides, and recombinant proteins** |                                |                  |
| D-glucose                               | Chem-Impex Int’l Inc.           | Cat # 00805      |
| Insulin                                 | Sigma Aldrich                   | Cat # I0516-5ML  |
| Leptin                                  | R&D Systems                     | Cat # 498-OB     |
| Ethanolamine-O-sulfate (EOS)            | Sigma Aldrich                   | Cat # 06720-100G |
| Vigabatrin                              | United States Pharmacopeia      | Cat # 1712001    |
| H³-2-deoxy-D-glucose                    | Perkin Elmer                    | Cat # NET328A001MC |
| 3-[¹H]-D-glucose                       | Perkin Elmer                    | Cat# NET331C001MC |
| ¹⁴C-2-deoxyglucose                      | Perkin Elmer                    | Cat# NEC495A001MC |
| TRIzol® LS Reagent                      | Life Technologies              | Cat # 10296010   |
| iTaq™ Universal SYBR® Green Supermix    | Bio-Rad Laboratories            | Cat # 172-5121   |
| **Critical commercial assays**          |                                |                  |
| Glucose Oxidase Assay                   | Pointe Scientific Inc.          | Cat # G7519      |
| Insulin ELISA                           | Alpco                           | Cat # 80-INSMUS-E01,E10 |
| GABA ELISA                              | Labor Diagnostika Nord          | Cat # BA E-2500  |
| Glucagon ELISA                          | Merckodia                       | Cat # 10-1281-01 |
| cGMP ELISA                              | Enzo Life Sciences              | Cat # ADI-900-164 |
| Quant-IT PicoGreen dsDNA Assay Kit      | Invitrogen                      | Cat # P7589      |
| Verso cDNA Synthesis Kit                | Thermo Scientific Inc.         | Cat # AB-1453/B  |
| **Deposited data**                      |                                |                  |
| Raw Data                                | This Paper                      | Mendeley Data: https://doi.org/10.17632/h2bvww478j6.1 |
| RNA-seq Data                            | This Paper                      | NCBI GEO: GSE144414 |
| **Experimental models: organisms/strains** |                                |                  |
| Mouse: C57BL6/J                         | Jackson Laboratories            | JAX stock 000664 |
| **Oligonucleotides**                    |                                |                  |
| 5′→3′ ACT₅ F: TCGGTGACATCAAAGAGAAG      | Integrated DNA Technologies     | N/A              |
| 5′→3′ ACT₅ R: GATGCCACAGGATCCATA         | Integrated DNA Technologies     | N/A              |
| 5′→3′ ABAT F: CTGAACACAATCCAGATGCAGA     | Integrated DNA Technologies     | N/A              |
| 5′→3′ ABAT R: GGTGTAACCTATGGCCACAG       | Integrated DNA Technologies     | N/A              |
| 5′→3′ INS F: GCTTCTTCTACACACCCTGTG       | Integrated DNA Technologies     | N/A              |
| 5′→3′ INS R: AGCACTGACTTACAATGCCAC       | Integrated DNA Technologies     | N/A              |
| 5′→3′ NPY F: TCTGCTGTTTGGGACTCTT         | Integrated DNA Technologies     | N/A              |
| 5′→3′ NPY R: CTTGCCCATATCTCTGCTGGTG      | Integrated DNA Technologies     | N/A              |
| 5′→3′ AgRP F: GTACGGCCACGAACTCTCTGT      | Integrated DNA Technologies     | N/A              |
| 5′→3′ AgRP R: TCCCCGTGCCCTTGGCCCA        | Integrated DNA Technologies     | N/A              |
| 5′→3′ POMC F: GGTAAGGGTGTTCCCAACGT       | Integrated DNA Technologies     | N/A              |
| 5′→3′ POMC R: GACCTGCTCCAAGCTTAAAGG      | Integrated DNA Technologies     | N/A              |
| 5′→3′ GABA-T ASO: AAGCTATGGACTCTG        | IONIS Pharmaceuticals, Inc.     | Cat # 1160575    |
| 5′→3′ Scramble control ASO: GGCCAATAGCGGTCA | IONIS Pharmaceuticals, Inc.     | Cat # 549144    |

Software and algorithms (Continued on next page)
RESOURCE AVAILABILITY

Lead contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Benjamin Renquist (bjrenquist@arizona.edu).

Materials availability
The Antisense Oligonucleotides generated in this study are intellectual property of Ionis Pharmaceuticals (Carlsbad, CA).

Data and code availability
The datasets generate during this study are available at Mendeley Data: https://doi.org/10.17632/h2bww478j6.1. The RNS-seq data has been deposited into the NCBI GEO database under accession number GEO: GSE144414.

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Animals
All studies were conducted using male wild-type C57BL/6J mice purchased from Jackson Laboratories or bred in-house (Bar Harbor, ME). Mice were kept on a 14-hour light/10-hour dark schedule and housed 3-5 mice per cage until 1 week prior to study initiation, at which point animals were individually housed. We conducted studies in lean chow fed mice (7013 NIH-31, Teklad WI, 3.1 kcal/g, 18% kcal from fat, 59% kcal from carbohydrate, 23% kcal from protein) at 12-16 weeks of age. Studies in diet-induced obese mice dosed intraperitoneally with GABA transaminase inhibitors, mice treated with ethanolamine-O-sulfate in their drinking water, and mice treated with GABA-T targeted or scramble control antisense oligonucleotides (ASO) were performed after 8-10 weeks on a high fat diet (TD 06414, Teklad WI, 5.1 kcal/g, 60.3% kcal from fat, 21.3% kcal from carbohydrate, 18.4% kcal from protein; 20-26 weeks of age). For ASO studies, mice were stratified by body weight and assigned to an injection treatment (control or GABA-T). Studies in obese vagotomy and sham mice were performed after 9 weeks of high fat diet feeding. Unless fasted, mice had ad libitum access to food and water. All studies were approved by The University of Arizona Institutional Animal Care and Use Committee.

Hepatic Vagotomy Surgeries
Surgeries were performed in 12-week old male C57BL/6J mice under isoflurane anesthesia. Mice were randomly assigned to a surgical group (sham or vagotomy). A ventral midline incision through the skin and peritoneum allowed us to isolate the hepatic vagus nerve as it branched from the esophagus. In vagotomized mice, we severed the hepatic vagal nerve, while it remained intact in sham operated mice. The peritoneum was sutured with absorbable polyglactin 910 suture and the skin with nylon suture. Mice were given a single post-operative dose of slow release formulated buprenorphine analgesic (1.2 mg/kg slow release, sub-cutaneous). We monitored food intake and body weight daily and removed sutures 7 days post-operation.

Human Subjects
A total of 19 men and women with obesity (age 45 ± 3 years old, 2 men and 17 women) who were scheduled for bariatric surgery at Barnes-Jewish Hospital in St. Louis, MO participated in this study, which was conducted at Washington University School of Medicine in St. Louis. Subjects provided written, informed consent before participating in this study, which was approved by the Human Research Protection Office at Washington University School of Medicine in St. Louis, MO (ClinicalTrials.gov Database: NCT00981500).
METHOD DETAILS

Antisense Oligonucleotide Studies
Wild-type lean or diet-induced obese mice received twice-weekly intraperitoneal injections (12.5 mg/kg; 0.1 mL/10 g body weight) of murine GABA-Transaminase (GABA-T) targeted antisense oligonucleotides (ASO; IONIS 1160575; 5’- GGCCAATACGCCGTCA-3’) or scramble control ASO (IONIS 549144; 5’- GGCGAATACCGCTCA-3’) for 1 or 4 weeks prior to experimentation. The control ASO does not have complementarity to known genes and was employed to demonstrate the specificity of target reduction. 2, 4- constrained 2-O-ethyl (cEt) ASOs were synthesized at Ionis Pharmaceuticals (Carlsbad, CA) as described previously (Seth et al., 2010). Treatment with this GABA-T targeted ASO reduces hepatic GABA-T mRNA by 98% in adult mice within 1 week (Figure 2A). For studies after 1 week of ASO injections, we performed an OGTT (day 8), ITT (day 10), and mice were sacrificed to assess liver slice GABA release (day 12). For studies after 4 weeks of ASO injections, we performed an OGTT (day 29), ITT (day 30), and completed all additional studies within 1 week while continuing biweekly ASO injections before mice were sacrificed to assess liver slice GABA release.

GABA Transaminase Inhibitor Studies
Wild-type lean and obese mice were randomly divided into treatment groups and dosed daily with 8 mg of ethanalamine-O-sulfate (EOS; Sigma-Aldrich, St. Louis, MO), vigabatrin (United States Pharmacopeia, Rockville, MD) or PBS. Obese sham and vagotomy mice were dosed daily with 8 mg of EOS. In all cases, basal bleedings were taken prior to initiation of an ITT. Lean mice received treatment by oral gavage (0.3 mL/mouse) while obese mice were treated by intraperitoneal injection (0.3 mL/mouse). Pre-treatment studies were conducted in the week immediately prior to beginning drug administration. Daily doses took place at 9 am each day and oral glucose tolerance tests (OGTT) and insulin tolerance tests (ITT) were performed on the third and fourth days of treatment in lean mice, respectively. In wild-type obese mice, OGTT and ITT were performed on the fourth day of treatment in separate cohorts. On the fifth day of treatment we preformed 2DG clearance studies. In sham/vagotomy mice, OGTT and ITT were performed on the fourth and fifth day of treatment, respectively. After a 2-week washout period without treatment injection, a basal bleed and bleed 15 minutes after an oral glucose gavage (2.5 mg/kg) to determine oral glucose stimulated insulin secretion were performed.

In a separate set of studies, an ITT was performed in obese mice to establish insulin resistance. Subsequently, EOS was provided ad libitum in the water (3 g/L) for 4 days. An OGTT and ITT were performed on days 3 and 4 of treatment, respectively. The water was then removed, and an ITT was performed 2 weeks later to establish the timing of restoration of insulin resistance after drug removal.

Food Intake Studies
We measured food weight and body weight at 6am and 6pm for the first 14 days of control or GABA-T ASO injections in lean and obese wild-type mice (Figure 6) and GABA-T ASO injections in sham and vagotomy mice (Figure S8A–S8D). Weeks 3 and 4 food and body weight measurements were taken at 6pm on day 21 and 28 of ASO injections.

Fast-Induced Refeeding
Mice were housed on wood chip bedding (Harlan Laboratories; Cat #7090 Sani-Chips) to limit consumption of nutrients from bedding during the fasting period. Mice were fasted for 16 hours beginning at 5pm and food was returned at 9am. Food and body weight were measured at 10am, 11am, and 1pm to determine 1, 2, and 3-4 hour fast-induced refeeding.

Leptin Food Intake Study
Lean mice or diet-induced obese control or GABA-T targeted ASO treated mice received an intraperitoneal injection of phosphate buffered saline (PBS; 0.1 mL/10 g body weight) on day 1 and leptin (2 mg/kg; 0.1 mL/10 g body weight; CAT# 498-OB, R&D Systems, Minneapolis, MN) on day 2 at 6 am. Mice were not fasted before injections. Food and body weight were measured every day at 6am and 6pm.

ASO Energy Expenditure and Body Composition
Energy expenditure studies and body composition measurements were performed by the UC Davis Mouse Metabolic Phenotyping Center. Twelve male DIO (C57BL/6J, strain 380050) mice were sent to UC Davis from the Renquist Lab at ~20 weeks of age and were acclimated for 2 weeks on investigator provided diet (Research diets D12492). Mice were injected IP with control or ABAT ASO (12.5 mg/kg) twice a week for 4 weeks (8 injections total). Energy expenditure and physical activity were evaluated in 6 saline and 6 ABAT ASO treated mice by indirect calorimetry in the CLAMS (Comprehensive Lab Animal Monitoring System, Columbus Instruments) system three times at baseline (~3), 7, and 28 days post first ASO injection. Body composition was assessed under isoflurane anesthesia by DEXA after each CLAMS run. Animals were allowed to recover from anesthesia before returning to their home cage except for the final (8th) DEXA run, after which animals were terminated and no tissues collected. Animals were acclimated to the CLAMS cages for 48 hours and to the light and temperature-controlled chamber for 24 hours prior to testing. Animals were held and calorimetry data was collected for 48 hr. Analyzed data constitutes data collected from 48 hours of continuous measurement (2 light/2 dark cycles). Oxygen consumption and carbon dioxide production were measured and used to calculate energy expenditure (or heat production, kilocalories (kcal)) and respiratory exchange ratio (RER: VCO2/VO2). Cage-mounted sensors detected and
recorded measurements of physical activity, food intake and water intake. Body composition was measured by dual-energy X-ray absorptiometry under isoflurane anesthesia, using a Lunar PIXImus II Densitometer (GE Medical Systems, Chalfont St. Giles, UK) immediately after completion of the indirect respiration calorimetry measurements.

**EOS Body Composition**

Body composition was assessed in diet-induced obese mice on day 0 and 7 days after continuous provision of EOS in the drinking water (3 g/L) using an EchoMRI 900 with A10 insert for mice. We performed calibration daily and had the water stage set to on.

**Hyperinsulinemic Euglycemic Clamps**

Clamps were performed as previously described (Ayala et al., 2011). Briefly, one week prior to the experiment, diet-induced obese mice underwent surgical catheterization of the jugular vein under isoflurane anesthesia. Mice were given a single post-operative dose of slow release formulated buprenorphine analgesic (1.2 mg/kg slow release, sub-cutaneous) and food and body weight were assessed daily for 1 week. The same day following surgery completion mice received their first injection of either the scramble control or GABA-T targeted ASO (12.5 mg/kg; 0.1 mL/10 g body weight). Four days post-surgery mice received a second ASO injection, and clamps were performed 7 days after catheterization. Following a 5-h fast (starting at 0800h), clamps were performed using unrestrained, conscious mice. The clamp procedure consisted of a 90-min tracer equilibration period (~90 to 0 min), followed by a 120-min clamp period (0 to 120 min). To begin the equilibration period, mice were infused with 3-[3H]-D-glucose (0.05 μCi/μl in saline) at a rate of 10 μL/min for 2 minutes and then decreased to a rate of 1 μL/min for the remaining 90 minutes. All blood was collected from the tip of the tail in heparinized capillary tubes and immediately spun down to collect plasma for tracer and insulin analysis. All time points during the clamp are relative to the start of insulin infusion at time 0. Blood for tracer and insulin analysis was taken at ~10 and 0 minutes. At 0 minutes mice were infused with donor blood (5 μL/min continuously throughout study), insulin (4 μIU/kg/min; pump rate 1 μL/min continuously throughout study), and a variable infusion of 3-[3H]-D-glucose (0.05 μCi/μl in 50% dextrose) to maintain euglycemia. Glucose was assessed from whole-blood directly from the tail tip by glucometer (Manufacture # D2ASCCONK1T, Bayer, Leverkusen, Germany) every 10 minutes for 120 minutes starting at time 0. The glucose infusion rate was adjusted to maintain a blood glucose concentration in the range of 100-120 mg/dL. Blood for tracer measurements was taken at 80, 90, 100, and 120 minutes, and blood for insulin was taken at 100 and 120 minutes. To estimate insulin-stimulated glucose fluxes in tissues, mice were given a bolus of 14C-2-deoxyglucose (12 μCi in 48 μL follow by a 100 μL saline flush) after the 120min time point. Blood samples were collected 2, 10, and 25 minutes following the bolus. Mice were anesthetized with isoflurane using the bell-jar method and the soleus, quadricep, calf, white adipose tissue, and perirenal adipose tissue were collected and immediately frozen in liquid nitrogen for analysis of tissue specific glucose uptake. Plasma samples were deproteinized using barium hydroxide and zinc sulfate and tracer analysis and tracer standards was processed as described (Ayala et al., 2011). Plasma glucose was analyzed by colorimetric assay (Cat. # G7519, Pointe Scientific Inc., Canton MI) from the samples collected for tracer measurement. Plasma insulin was analyzed by enzyme-linked immunosorbent assay (ELISA; Cat. # 80-INSMSU-E01,E10, Alpco, Salem, NH).

**Oral Glucose Tolerance Test**

Oral glucose (2.5 g/kg; 0.1 mL/10 g body weight; Chem-Impex Int’l Inc., Wood Dale, IL) was given to 4 hour fasted individually housed mice. All glucose tolerance tests began at 1 pm and glucose was measured in whole blood, collected from the tail vein, by glucometer (Manufacture # D2ASCCONK1T, Bayer, Leverkusen, Germany) at 0, 15, 30, 60, 90, and 120 minutes after glucose gavage. Blood for serum insulin (oral glucose stimulated insulin secretion; OGISIS) and glucose determination was collected from the tail vein 15 minutes following glucose administration.

**Insulin Tolerance Test**

Intraperitoneal insulin (0.5 U/kg; 0.1 mL/10 g body weight; Sigma Aldrich, St. Louis, MO) was given to 4 hour fasted individually housed mice. All insulin tolerance tests began at 1 pm and glucose was measured in whole blood, collected from the tail vein, by glucometer (Manufacture # D2ASCCONK1T, Bayer, Leverkusen, Germany) at 0, 30, 60, 90, and 120 minutes after insulin injection.

**Liver Slice Explant Studies**

Liver slices from ASO treated mice were incubated ex vivo to measure hepatic GABA release. A peristaltic pump perfusion system was used to deliver warmed KH buffer to the liver through the portal vein. Briefly, mice were anesthetized with an intraperitoneal injection of ketamine (10 mg/mL) and diazepam (0.5 mg/mL). Once mice were unresponsive, an incision in the lower abdomen through the skin and peritoneal membrane was made vertically through the chest along with transverse incisions on both sides to expose the liver. A 30-gauge needle was inserted into the hepatoporal vein to blanch the liver. The inferior vena cava was cut to relieve pressure in the circulatory system and allow blood to drain. The perfusion continued for several minutes at a rate of 4 mL/minute until the liver was completely blanched. The liver was removed and washed in warm PBS before being sliced into 0.2 mm slices using a Thomas Sadie-Riggs Tissue Slicer. Two liver slices were taken from each mouse. Tissue slices were placed individually into a well on a 12-well plate pre-filled with 1mL of KH buffer that had been sitting in an incubator set to 37° C and gassed with 5% CO2. Liver slices were incubated in the initial well for 1 hour to stablish before being transferred to a fresh well pre-filled with KH buffer. After 1 hour in the second well, tissue and media were collected. Liver slice samples and KH media samples from both wells of each mouse
were pooled. Liver slices were snap frozen in liquid nitrogen, while media was centrifuged for 5 minutes at 10,000xg at 4 °C to remove tissue debris and both were frozen and stored at −80 °C pending analysis.

GABA Analysis
For all liver slice GABA release data, we thawed the media collected from the ex vivo hepatic slice culture on ice. We then measured GABA in the supernatant using a commercially available ELISA (REF# BA E-2500, Labor Diagnostika Nord, Nordhorn, Germany). μmol GABA concentrations were corrected for recovery of liver slice DNA concentrations.

3H-2-deoxy-D-glucose Uptake Studies
On the fifth day of EOS or PBS treatment 3H-2-deoxy-D-glucose (2DG; 10 uCi/mouse; PerkinElmer, Waltham, MA) was given to 4-hour fasted individually housed mice. Studies were performed in 2 cohorts on 2 different days. 2DG was given by oral gavage in a solution of glucose (2.5 g/kg) and each mouse received the same dose based off the average body weight for their cohort (0.1 mL/10 g body weight). Mice were anesthetized by isoflurane and sacrificed by cervical dislocation 45 minutes following oral gavage. Liver, soleus, quadriceps femoris, and gonadal white adipose tissue were collected, weighed, and dissolved overnight in 1N NaOH (0.5 mL/50 mg tissue) at 55 °C on a shaker plate. 0.5 mL of dissolved tissue was added to 5 mL of scintillation cocktail (Ultima Gold, PerkinElmer, Waltham, MA) and disintegrations per minute (DPM) were measured using a LS 6500 Multipurpose Scintillation Counter (Beckman Coulter, Brea, CA). DPM/g tissue weight was determined for each tissue and normalized based on a correction factor calculated by the average total DPM/g for all tissues divided by the total DPM/g for all tissues of the individual mouse.

cGMP Analysis
On the fifth day of EOS or PBS treatment, mice were sacrificed and the quadriceps and soleus tissues were collected and frozen on dry ice. Prior to analysis, frozen quadriceps were powdered using a liquid nitrogen cooled mortar and pestle to obtain homogeneous muscle samples. 15-20 mg of quadriceps and the entire soleus tissue (6-12 mg) were homogenized in 200 μL of a 5% trichloroacetic acid solution. Following 15 minutes of centrifugation at 3,000xg at 4 °C, supernatant was transferred to a fresh tube for analysis of muscle cGMP by enzyme-linked immunosorbent assay (ELISA; ADI-900-164, Enzo Life Sciences, Farmingdale, NY).

Liver Analysis
Prior to analysis, frozen liver slices were powdered using a liquid nitrogen cooled mortar and pestle to obtain homogeneous liver samples. To measure liver DNA content (ng dsDNA/g tissue), 10-20 mg of powdered liver was sonicated in 500 μL DEPC H2O and dsDNA determined by fluorometric assay (Cat. # P7589, Invitrogen, Waltham, MA). Whole liver and hypothalamic mRNA were isolated from powdered liver samples with TRI Reagent® (Life Technologies, Grand Island, NY) and phenol contamination was eliminated by using water-saturated butanol and ether as previously described (Krebs et al., 2009). cDNA was synthesized by reverse transcription with Verso cDNA synthesis kit (Thermo Scientific, Inc., Waltham, MA) and qPCR performed using SYBR 2X mastermix (Bio-Rad Laboratories, Hercules, CA) and the Biorad iQ™5 iCycler (Bio-Rad Laboratories, Hercules, CA). Expression of GABA-Transaminase (ABAT), β-actin (ACTβ), insulin (Ins), neuropeptide Y (NPY), agouti related peptide (AgRP), and pro-opiomelanocortin (POMC) mRNA were measured using the following primers (5’ → 3’): ABAT, Forward – CTGACACATCCGAGAATGG Reverse – GGTTGGAACC TATGGGCACAG; ACTβ, Forward – TCGTGACATCAAGAAGAAAG Reverse – GATGCAAGAGTCCATAA; Ins, Forward – GCTTC TTCTACACACCCATGTC Reverse – AGACCTGATCTAAATGCCAC; NPY, Forward – GCTCCCTGATTTGACCGTTC Reverse – CTG GCCATATCTGTGCGGAGG; AgRP, Forward – GACGGCCACGAAGACTTCTGTG Reverse – TCCGCTGCTGGCCCAA; POMC, Forward – GGTTAAGGGTACCCCAAAGT Reverse – GACCTGGCTCCAGCCTAGG. LinReg PCR analysis software was used to determine the efficiency of amplification from raw output data (Ramakers et al., 2003). ACTβ served as the reference gene for liver and brain tissue, and Ins served as the reference gene for pancreas tissue for calculating fold change in ABAT gene expression using the efficiency-ΔΔCT method (Livak and Schmittgen, 2001).

Serum Assays
Within 2 hours of collection, blood was left to clot at room temperature for 20 minutes. Thereafter, the blood was centrifuged at 3,000xg for 30 minutes at 4 °C and serum was collected. Serum was stored at −80 °C until metabolite and hormone analyses. We used a colorimetric assay to analyze serum glucose (Cat. # G7519, Pointe Scientific Inc., Canton MI). Serum insulin was analyzed by enzyme-linked immunosorbent assay (ELISA; Cat. # 80-INSMSU-E01.E10, Alpco, Salem, NH). Serum glucagon was analyzed by enzyme-linked immunosorbent assay (ELISA; Cat. # 10-1281-01, Mercodia, Uppsala, Sweden) from tail vein blood collected at 9 am from fed mice.

Studies Conducted in Human Subjects
Intrahepatic triglyceride content was determined by using magnetic resonance imaging (3.0-T superconducting magnet; Siemens, Iselin, NJ) in the Center for Clinical Imaging Research. A 7-hour (3.5-h basal period and 3.5-h insulin infusion period) hyperinsuline-
μmol·kg fat-free mass (FFM)⁻¹·min⁻¹) and fasting plasma insulin concentration (in mU/L). For liver RNA sequencing (RNA-seq), liver tissue was obtained by needle biopsy during the bariatric surgical procedure, before any intra-operative procedures were performed. Liver tissue was rinsed in sterile saline, immediately frozen in liquid nitrogen, then stored at −80°C until RNA extraction. Total RNA was isolated from frozen hepatic tissue samples by using Trizol reagent (Invitrogen, Carlsbad, CA). Library preparation was performed with total RNA and cDNA fragments were sequenced on an Illumina HiSeq-4000. The fragments per kilobase million reads upper quartile (FPKM-UQ) values were calculated and used for further gene expression analyses. All RNA-seq data used in this study have been deposited into the NCBI GEO database under accession number GEO: GSE144414.

QUANTIFICATION AND STATISTICAL ANALYSIS

Statistics
We analyzed the data in SAS Enterprise Guide 7.1 (SAS Inst., Cary, NC), using a mixed-model ANOVA for all analyses except the multivariate regression analyses performed on human clinical data. ANOVA tests do not have a one-tailed versus two-tailed option, because the distributions they are based on have only one tail. When comparisons between all means were required, we used a Tukey’s adjustment for multiple comparisons. When comparisons of means were limited (e.g., only within a time point or treatment), we used a Bonferonni correction for multiple comparisons. For the analysis of ITT and OGTT, repeated-measures ANOVA were performed by including time point in the analysis. Analyses were conducted separately for chow and HFD fed mice. For the studies using the GABA-T inhibitors the main effect was treatment (PBS, Vigabatrin, or EOS). For EOS treated sham and vagotomy mice the main effects were surgery (sham or vagotomy) and treatment (PBS or EOS). Pre-, during, and post-treatment measures were taken for basal glucose, insulin, and glucose stimulated insulin, thus a repeated-measure analysis including time (pre-, during, or post-treatment) was performed separately within each injection or surgical treatment. For analysis of the effect of EOS on 2DG uptake and cGMP, analysis was performed separately for each tissue. For ASO studies the main effect was injection treatment (control of GABA-T ASO). For the vagotomy analyses the main effect was surgery (sham or vagotomy). Pre-treatment and ASO week 4 measures were taken for basal glucose, insulin, and the glucose:insulin ratio, thus a repeated-measure analysis including time (pre-, or week 4-treatment) was performed separately within each injection or surgical treatment. A multivariate regression analysis was performed on data from human clinical patients using IHTG content, ABAT mRNA, and SLC6a12 mRNA as explanatory variables for variations in serum insulin, HOMA-IR, M-Value, and Glucose Rd. Statistics performed by the UC Davis Mouse Metabolic Phenotyping Center are described as follows: data are presented as means ± SEM and a Student t test was used to test for significant differences between groups. Multiple linear regression analysis (analysis of covariance, ANCOVA) was used to assess the impact of covariates (e.g., body weight or lean mass) on energy expenditure. The EE ANCOVA analysis done for this work was provided by the NIDDK Mouse Metabolic Phenotyping Centers (MMPC, https://www.mmpc.org) using their Energy Expenditure Analysis page (https://www.mmpc.org/shared/regression.aspx) and supported by grant DK076169. All insulin tolerance tests are presented as a percentage of baseline glucose in main and supplemental figures, and additionally presented as raw glucose values in Figure S9. All graphs were generated using GraphPad Prism 8 (GraphPad Software Inc., La Jolla, CA). Information on replicates and significance is included in the figures. Error bars are defined in the figure legends.